Skip to main content

GW Pharmaceuticals stock rises 10% after beating revenue expectations for marijuana-derived drug

GW Pharmaceuticals PLC shares rose more than 10% in the extended session Tuesday, after the company reported better-than-expected sales from its cannabis-derived epilepsy treatment drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.